The increase in IRF1 and inhibition of proliferation following PARP9 silencing have also been observed in prostate cancer models, as well as a reduction in proliferation and chemo resistance following PARP9 or PARP14 inhibition, in both a STAT-1-dependent and independent manner, respectively [30,55]. Here, PARP9 is linked to prostate carcinoma.